Evidence map›Paper›PMID 42809144›Full record

ArticleJournal of applied genetics2026

Rapid and reliable molecular diagnosis of oculopharyngeal muscular dystrophy: a cost-effective alternative for PABPN1 gene (GCN)n repeat analysis.

M Vital, E Salazar, C Acordagoitia, C Vázquez, Patricia Esperón

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M VitalMolecular Genetic Unit, School of Chemistry, Universidad de la República, General Flores 2124, Montevideo, CP1800, Uruguay.
E SalazarPoliclínica de Enfermedades Neuromusculares, Hospital de Clínicas, Av. Italia s/n, Piso 2, Montevideo, CP1600, Uruguay.
C AcordagoitiaPoliclínica de Enfermedades Neuromusculares, Hospital de Clínicas, Av. Italia s/n, Piso 2, Montevideo, CP1600, Uruguay.
C VázquezPoliclínica de Enfermedades Neuromusculares, Hospital de Clínicas, Av. Italia s/n, Piso 2, Montevideo, CP1600, Uruguay.
Patricia EsperónMolecular Genetic Unit, School of Chemistry, Universidad de la República, General Flores 2124, Montevideo, CP1800, Uruguay. pesperon@fq.edu.uy.ORCID http://orcid.org/0000-0002-3080-5702

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset autosomal dominant disorder caused by an abnormal (GCN)n trinucleotide repeat expansion in exon 1 of the polyadenylate-binding protein nuclear 1 (PABPN1) gene. This expansion increases the polyalanine tract from a normal 10 to 11-18 repeats, leading to progressive muscle weakness. We evaluated the advantages of fragment analysis via a capillary electrophoresis system using a Gelbot device as a cost-effective alternative to Sanger sequencing for determining (GCN)n repeat numbers. A total of 90 genomic DNA samples primarily analyzed by Sanger sequencing were submitted to the above-mentioned capillary electrophoresis. This showed full concordance in the detection of expanded alleles. Compared to DNA sequencing, fragment analysis offered a faster turnaround time, a simpler workflow, and more straightforward result interpretation. Notably, this method requires less initial expenditure on instruments and avoids the need for fluorescently labelled primers and other reagents, which significantly reduces implementation costs. In conclusion, capillary electrophoresis-based fragment analysis provides a reliable, rapid, and accessible method for PABPN1 screening. It represents a practical diagnostic alternative for OPMD, particularly in laboratories with limited resources.

Indexed as

Capillary electrophoresisFragment analysisGCN repeatsOculopharyngeal muscular dystrophySequencing

Identifiers

PMID42809144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.